Radiant Biotherapeutics is a startup developing antibody drugs with enhanced binding capabilities. Their technology, called Multabodies, allows antibodies to bind to multiple targets, leading to improved efficacy and potency. The company’s research focuses on treatments for cancer and infectious diseases, with a particular emphasis on targeting the 4-1BB receptor. Radiant has received funding from the Bill & Melinda Gates Foundation and has partnerships with big pharma companies like GSK and Regeneron Pharmaceuticals. Their goal is to bring their 4-1BB program into clinical trials by 2026. Funding for Radiant’s research and development efforts has been supported by various investors and partners.
Source link
Gates Foundation Joins Radiant Bio’s $35M Round for Antibody Drugs With ‘Better Grip’
